About Aether Biomachines
Aether Biomachines specializes in engineering enzymes for clients in various industries, helping them manufacture complex products at lower costs. The company uses proprietary hardware to conduct massively parallel experiments, allowing them to generate large data sets that help identify novel biocatalysts. This unique capability enables Aether to design enzymes tailored to specific chemical processes within a client's timeline. Unlike competitors, Aether has the ability to search through a vast sequence space of enzymes, creating a searchable index similar to how Google mapped the internet. The company focuses on high-value contracts and has attracted significant investment due to its potential to drive a new industrial revolution.
Menlo Park, CaliforniaHeadquarters
2017Year Founded
$47.7MTotal Funding
SERIES_ACompany Stage
Data & Analytics, BiotechnologyIndustries
51-200Employees
Risks
Competition from Zymergen and Ginkgo Bioworks threatens Aether Bio's market position.
Rapid AI advancements could render Aether Bio's technology obsolete if not updated.
Regulatory challenges in biotechnology may impact Aether Bio's operations.
Differentiation
Aether Bio uses machine learning to repurpose enzymes for new compound creation.
Proprietary hardware allows massively parallelized experimentation, generating large datasets.
First company to search sequence space for novel biocatalysts, enhancing enzyme design.
Upsides
Increased demand for sustainable manufacturing boosts Aether Bio's enzyme engineering services.
AI-driven drug discovery opens collaboration opportunities with pharmaceutical companies.
Synthetic biology market expansion offers significant growth potential for Aether Bio.
Funding
Total raised$47.66 M
Latest valuation$245.00 M
StageSERIES_A
SERIES A
7/31/2023$49
$245.00 M